Molecular profiling of melanoma tumors explains differences in survival after T cell therapy

Posted by on November 28, 2017 1:18 pm
Categories: health

The more times metastasized melanoma has mutated and the patient’s immune system has been activated against the tumor – the better the chances of survival after immunotherapy.

Leave a Reply

Your email address will not be published. Required fields are marked *